サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
表紙：下気道治療薬の世界市場：2023-2030
市場調査レポート
商品コード
1290356

下気道治療薬の世界市場：2023-2030

Global Lower Respiratory Tract Therapeutics Market - 2023-2030
出版日: | 発行: DataM Intelligence | ページ情報: 英文 195 Pages | 納期: 約2営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報（例：国別セグメント）の追加などの対応が可能です。　 詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=156.76円
下気道治療薬の世界市場：2023-2030
出版日: 2023年06月12日
発行: DataM Intelligence
ページ情報: 英文 195 Pages
納期: 約2営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

市場概要

下気道治療薬の世界市場規模は、2022年に323億1,290万米ドルに達し、2030年には最大562億5,170万米ドルに達することで有利な成長が予測されます。世界の下気道治療薬市場は、予測期間中（2023-2030年）に7.3%のCAGRを示すと予測されています。主な市場動向は、業界の煙害関連や喫煙による呼吸器疾患の増加が広がっていることです。

例えば、2023年4月、ミズーリ州のキャンペーンは「タバコは変わる」を開始し、子供を中毒に誘惑するさまざまなキャンディー味のタバコ製品について親を啓蒙しています。それはタバコをめぐる現実でもあり、特に電子タバコに関しては、そうです。

下気道治療薬は、下気道感染症の疾患と障害の診断、治療、管理に焦点を当てています。これらの感染症は、産科間接死の重要な原因となっています。妊娠中の患者さんは、呼吸不全や蓄膿症などの合併症のリスクが高くなります。下気道治療薬は、喘息、COPD、呼吸器感染症、嚢胞性線維症など、さまざまな呼吸器疾患に対応するように設計されています。

下気道治療薬市場は、下気道疾患の有病率の増加、高齢化率の上昇、認知度・診断度の向上、政府の取り組みやヘルスケア政策、環境要因（大気汚染、気候変動、アレルゲンなど）、技術進歩などの要因によって牽引されています。

例えば、2023年4月、世界保健機関（WHO）は、細菌学的に確定された結核の増加や薬剤耐性の検出、診断までの時間の短縮のために、WHO推奨の迅速診断薬（WRD）へのユニバーサルアクセスを達成するためのベンチマークを設定した、迅速結核診断薬へのユニバーサルアクセスを発表しました。WHOが推奨する迅速診断薬は、精度が高く、費用対効果が高く、治療開始までの時間を短縮し、患者にとって重要なアウトカムに影響を与えるものです。

市場力学

下気道疾患の有病率の増加

下気道疾患の有病率の増加は、予測期間中の市場シェアを押し上げる主要因となっています。喘息、慢性閉塞性肺疾患（COPD）、肺炎、気管支炎などの下気道疾患は、世界のヘルスケアシステムに大きな負担を与えています。これらの疾患の有病率の増加は、効果的な治療薬を必要とする患者数の増加を意味し、市場需要の増加につながります。

例えば、血漿由来医薬品と革新的な診断ソリューションの世界リーダーであるGrifolsは、2023年5月、COPDの遺伝的リスクをスクリーニングする米国初の無料直接消費者向けプログラム、AlphaID at-home genetic health risk service（AlphaID At Home）を開始したと発表しました。

副作用のリスクが高い

喘息やCOPDの治療薬など、下気道治療薬に関連する副作用は、患者さんや医療従事者に安全性に関する懸念を抱かせる可能性があります。副作用のリスクは、患者さんの治療開始や継続を妨げる可能性があり、最適な疾病管理の欠如や市場需要の減少につながります。

下気道治療薬の安全性プロファイルを継続的にモニタリングすることは、副作用を効果的に特定し管理するために極めて重要です。ファーマコビジランスの取り組みは、副作用の早期発見と適切な管理を保証し、患者の信頼と市場の需要を維持するのに役立ちます。

COVID-19の影響分析

COVID-19のパンデミックは、下気道治療薬市場を含むヘルスケア産業に大きな影響を与えました。パンデミックは呼吸器系の健康の重要性を強調する一方で、他の呼吸器系疾患から資源や注意を逸らすことにもなりました。さらに、サプライチェーン、臨床試験、ヘルスケアサービスにおける混乱は、市場に課題を突きつけました。

パンデミックは、下気道治療薬に関する進行中の臨床試験を中断させました。COVID-19の研究を優先し、患者の安全を確保するために、多くの臨床試験が一時停止、遅延、変更されました。このような臨床試験活動の中断は、新しい治療法の開発および規制当局の承認を遅らせ、下気道治療薬の将来のパイプラインに影響を与える可能性があります。

ロシア・ウクライナ紛争分析

ロシア・ウクライナ紛争は、下気道治療薬市場に大きな影響を及ぼしています。この戦争は、新しい治療法の開発や臨床試験など、研究開発活動に支障をきたす可能性があります。限られた資源、インフラの損傷、研究者の転居は、呼吸器治療薬研究の進展を妨げる可能性があります。

紛争は、過密状態、不衛生、移住による呼吸器感染症のリスク増加など、公衆衛生上の課題の一因となる可能性があります。これらの要因は、呼吸器系疾患の負担増につながり、下気道治療薬へのアクセス向上が必要となる可能性があります。

目次

第1章 調査手法とスコープ

  • 調査手法
  • 調査目的および調査範囲

第2章 定義と概要

第3章 エグゼクティブサマリー

  • 疾患タイプ別スニペット
  • 薬剤クラス別スニペット
  • 投与経路別スニペット
  • 販売チャネル別
  • エンドユーザー別
  • 地域別スニペット

第4章 市場力学

  • 影響要因
    • 促進要因
      • 下気道疾患の有病率の増加
      • 有害な環境要因
    • 抑制要因
      • 副作用のリスクが高い
      • 治療法の選択肢が限られている
    • 機会
      • 治療法の技術的進歩
    • 影響分析

第5章 産業分析

  • ポーターの5フォース分析
  • サプライチェーン分析
  • 価格分析
  • 法規制の分析

第6章 COVID-19の分析

  • COVID-19の分析
    • COVID-19の前のシナリオ
    • COVID-19実施中のシナリオ
    • COVID-19後のシナリオ
  • COVID-19の中での価格・ダイナミクス
  • 需給スペクトル
  • パンデミック時の市場に関連する政府の取り組み
  • メーカーの戦略的な取り組み
  • サマリー

第7章 疾患タイプ別

  • 気管支喘息
  • 慢性閉塞性肺疾患
  • 肺炎
  • 結核
  • 気管支炎
  • その他

第8章 薬剤クラス別

  • 抗生物質
  • 非ステロイド性抗炎症薬
  • 咳止め薬
  • 鼻腔充血除去剤
  • その他

第9章 投与経路別

  • 経口剤
  • 非経口剤
  • その他

第10章 流通チャネル別

  • 病院薬局
  • 小売薬局
  • オンライン薬局

第11章 エンドユーザー別

  • 病院
  • 専門クリニック
  • 在宅医療
  • その他

第12章 地域別

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • 南米
    • ブラジル
    • アルゼンチン
    • その他南米地域
  • アジア太平洋地域
    • 中国
    • インド
    • 日本
    • オーストラリア
    • その他アジア太平洋地域
  • 中東・アフリカ地域

第13章 競合情勢

  • 競合シナリオ
  • 市況ポジショニング/シェア分析
  • M&A（合併・買収）分析

第14章 企業プロファイル

  • F. Hoffmann-La Roche Ltd.
    • 会社概要
    • 製品ポートフォリオと説明
    • 財務概要
    • 主な発展状況
  • Teva Pharmaceutical Industries Ltd.
  • Sanofi S.A
  • Pfizer Inc.
  • GSK plc
  • Novartis AG
  • AstraZeneca
  • Johnson & Johnson Private Limited
  • Sun Pharmaceutical Industries Ltd.
  • Merck & Co., Inc

第15章 付録

目次
Product Code: PH558

Market Overview

The Global Lower Respiratory Tract Therapeutics Market size reached US$ 32,312.9 million in 2022 and is projected to witness lucrative growth by reaching up to US$ 56,251.7 million by 2030. The global lower respiratory tract therapeutics market is expected to exhibit a CAGR of 7.3% during the forecast period (2023-2030). The key market trend is the widespread increase in industry smoke-related and smoking respiratory diseases.

For instance, in April 2023, Missouri's campaign launched "Tobacco is Changing", to educate parents about the different candy-flavored tobacco products tempting children into addiction. It is also the reality of the tobacco landscape - especially when it comes to e-cigarettes.

Lower respiratory tract therapeutics focuses on the diagnosis, treatment, and management of diseases and disorders of lower respiratory tract infections These infections are an important cause of indirect obstetric death. Pregnant patients are at increased risk of complications such as respiratory failure and empyema. Lower respiratory tract therapeutics are designed to address a range of respiratory conditions such as asthma, COPD, respiratory infections, cystic fibrosis and so on.

The lower respiratory tract therapeutics market is driven by factors such as the increasing prevalence of lower respiratory tract diseases, the rising aging population, increasing awareness and diagnosis, government initiatives and healthcare policies, environmental factors (such as air pollution, climate change, and allergens), and technological advancements.

For instance, in April 2023, The World Health Organization (WHO) released Universal access to rapid tuberculosis diagnostics, setting benchmarks to achieve universal access to WHO-recommended rapid diagnostics (WRDs) to increase bacteriologically-confirmed TB and detection of drug resistance and reduce the time to diagnosis. WHO-recommended rapid diagnostics are highly accurate, cost-effective, reduce the time to treatment initiation, and impact patient-important outcomes.

Market Dynamics

Increasing Prevalence Of Lower Respiratory Tract Diseases

The increasing prevalence of lower respiratory tract diseases is the major factor driving the market share during the forecast period. Lower respiratory tract diseases, such as asthma, chronic obstructive pulmonary disease (COPD), pneumonia, and bronchitis, impose a significant burden on global healthcare systems. The growing prevalence of these diseases means a larger patient population in need of effective therapeutics, leading to increased market demand.

For instance, in May 2023, Grifols, a global leader in plasma-derived medicines and innovative diagnostic solutions, announced that it launched its AlphaID at-home genetic health risk service (AlphaID At Home), the first-ever free direct-to-consumer program in the U.S., to screen for the genetic risk of COPD.

Higher Risk Of Adverse Effects

Adverse effects associated with lower respiratory tract therapeutics, such as medications used for asthma or COPD, can raise safety concerns among patients and healthcare professionals. The risk of adverse effects may discourage patients from initiating or continuing treatment, leading to suboptimal disease management and reduced market demand.

Continuous monitoring of the safety profile of lower respiratory tract therapeutics is crucial to identify and manage adverse effects effectively. Pharmacovigilance efforts help ensure early detection and appropriate management of adverse effects, maintaining patient confidence and market demand.

COVID-19 Impact Analysis

The COVID-19 pandemic has had a profound impact on the healthcare industry, including the lower respiratory tract therapeutics market. While the pandemic has highlighted the importance of respiratory health, it has also diverted resources and attention away from other respiratory conditions. Additionally, disruptions in supply chains, clinical trials, and healthcare services have posed challenges for the market.

The pandemic has disrupted ongoing clinical trials for lower respiratory tract therapeutics. Many trials were paused, delayed, or modified to prioritize COVID-19 research and ensure patient safety. This interruption in clinical trial activities may delay the development and regulatory approval of new therapies, affecting the future pipeline of lower respiratory tract therapeutics.

Russia-Ukraine Conflict Analysis

The Russia-Ukraine conflict has had a significant impact on the lower respiratory tract therapeutics market. The war may disrupt research and development activities, including the development of new therapies or clinical trials. Limited resources, infrastructure damage, and the displacement of researchers can hinder progress in respiratory therapeutics research.

The conflict can contribute to public health challenges, including the increased risk of respiratory infections due to overcrowding, poor sanitation, and displacement. These factors can lead to a higher burden of respiratory diseases and may require increased access to lower respiratory tract therapeutics.

Segment Analysis

The global lower respiratory tract therapeutics market is segmented based on disease type, drug class, route of administration, distribution channel, end-user, and region.

Based on Disease Type, The Asthma Therapeutics Segment Is Expected To Dominate The Market Share

The market for asthma therapeutics held 45.3% of the global lower respiratory tract therapeutics market share in 2022. Asthma is a prevalent chronic respiratory condition affecting millions of people worldwide. The high prevalence of asthma contributes to a larger patient population requiring ongoing management and treatment, which drives the demand for asthma therapeutics.

Asthma management involves a range of therapeutics to control and prevent symptoms. These include bronchodilators (both short-acting and long-acting), inhaled corticosteroids, combination inhalers, leukotriene modifiers, and monoclonal antibodies targeting specific inflammatory pathways. The availability of multiple treatment options within the asthma therapeutics segment provides choices for healthcare professionals to tailor treatment plans to individual patient needs.

For instance, in May 2023, Alkem Laboratories, a leading pharmaceutical company, announced the launch of its initiative 'Reliever Free India' to raise awareness about Asthma among physicians and Asthma patients. This initiative aims to spread awareness of the hazards of over-usage of reliever medications and substitute it with SMART therapy i.e., needing only one inhaler for both 'daily' and 'reliever' asthma treatment.

Geographical Analysis

North America Holds The Largest Market Share Due To The High Disease Burden And Technological Advancements

North America held 38.1% market share for the lower respiratory tract therapeutics market in 2022 due to the high disease burden and technological advancements in treatment options. North America has a significant burden of lower respiratory tract diseases, including asthma, COPD, and respiratory infections. The region's population, lifestyle factors, environmental exposures, and healthcare infrastructure contribute to the prevalence of these conditions.

North America has witnessed significant technological advancements in the field of respiratory medicine. This includes the development of advanced inhalation devices, targeted biologics, digital health solutions, and precision medicine approaches for lower respiratory tract diseases. These technological advancements enhance treatment efficacy, patient convenience, and disease management, further strengthening the market share of North America.

Competitive Landscape

The major global players in the market include: F. Hoffmann-La Roche Ltd., Teva Pharmaceutical Industries Ltd., Sanofi S.A, Pfizer Inc., GSK plc, Novartis AG, AstraZeneca, Johnson & Johnson Private Limited, Sun Pharmaceutical Industries Ltd., and Merck & Co., Inc.

Why Purchase the Report?

  • To visualize the global lower respiratory tract therapeutics market segmentation based on disease type, drug class, route of administration, distribution channel, end-user, and region, as well as understand key commercial assets and players.
  • Identify commercial opportunities by analyzing trends and co-development.
  • Excel data sheet with numerous data points of lower respiratory tract therapeutics market-level with all segments.
  • PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
  • Product mapping available as Excel consisting of key products of all the major players.

The global lower respiratory tract therapeutics market report would provide approximately 54 tables, 46 figures, and 195 Pages.

Target Audience 2023

  • Manufacturers/ Buyers
  • Industry Investors/Investment Bankers
  • Research Professionals
  • Emerging Companies

Table of Contents

1. Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

  • 3.1. Snippet by Disease Type
  • 3.2. Snippet by Drug Class
  • 3.3. Snippet by Route of Administration
  • 3.4. Snippet by Distribution Channel
  • 3.5. Snippet by End-User
  • 3.6. Snippet by Region

4. Dynamics

  • 4.1. Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Increasing prevalence of lower respiratory tract diseases
      • 4.1.1.2. Harmful environmental factors
    • 4.1.2. Restraints
      • 4.1.2.1. Higher risk of adverse effects
      • 4.1.2.2. Limited treatment options
    • 4.1.3. Opportunity
      • 4.1.3.1. Technological advancements in treatment procedures
    • 4.1.4. Impact Analysis

5. Industry Analysis

  • 5.1. Porter's 5 Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis

6. COVID-19 Analysis

  • 6.1. Analysis of COVID-19
    • 6.1.1. Scenario Before COVID-19
    • 6.1.2. Scenario During COVID-19
    • 6.1.3. Scenario Post COVID-19
  • 6.2. Pricing Dynamics Amid COVID-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During the Pandemic
  • 6.5. Manufacturer's Strategic Initiatives
  • 6.6. Conclusion

7. By Disease Type

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 7.1.2. Market Attractiveness Index, By Disease Type
  • 7.2. Asthma*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. COPD
  • 7.4. Pneumonia
  • 7.5. Tuberculosis
  • 7.6. Bronchitis
  • 7.7. Others

8. By Drug Class

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 8.1.2. Market Attractiveness Index, By Drug Class
  • 8.2. Antibiotics*
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Non-Steroidal Anti-Inflammatory Drugs
  • 8.4. Cough Suppressants
  • 8.5. Nasal Decongestants
  • 8.6. Others

9. By Route of Administration

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 9.1.2. Market Attractiveness Index, By Route of Administration
  • 9.2. Oral*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Parenteral
  • 9.4. Others

10. By Distribution Channel

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.1.2. Market Attractiveness Index, By Distribution Channel
  • 10.2. Hospital Pharmacies*
    • 10.2.1. Introduction
    • 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 10.3. Retail Pharmacies
  • 10.4. Online Pharmacies

11. By End-User

  • 11.1. Introduction
    • 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 11.1.2. Market Attractiveness Index, By End-User
  • 11.2. Hospitals*
    • 11.2.1. Introduction
    • 11.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 11.3. Specialty Clinics
  • 11.4. Homecare
  • 11.5. Others

12. By Region

  • 12.1. Introduction
    • 12.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 12.1.2. Market Attractiveness Index, By Region
  • 12.2. North America
    • 12.2.1. Introduction
    • 12.2.2. Key Region-Specific Dynamics
    • 12.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 12.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 12.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.2.8.1. The U.S.
      • 12.2.8.2. Canada
      • 12.2.8.3. Mexico
  • 12.3. Europe
    • 12.3.1. Introduction
    • 12.3.2. Key Region-Specific Dynamics
    • 12.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 12.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 12.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.3.8.1. Germany
      • 12.3.8.2. The UK
      • 12.3.8.3. France
      • 12.3.8.4. Italy
      • 12.3.8.5. Spain
      • 12.3.8.6. Rest of Europe
  • 12.4. South America
    • 12.4.1. Introduction
    • 12.4.2. Key Region-Specific Dynamics
    • 12.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 12.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 12.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.4.8.1. Brazil
      • 12.4.8.2. Argentina
      • 12.4.8.3. Rest of South America
  • 12.5. Asia-Pacific
    • 12.5.1. Introduction
    • 12.5.2. Key Region-Specific Dynamics
    • 12.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 12.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 12.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 12.5.8.1. China
      • 12.5.8.2. India
      • 12.5.8.3. Japan
      • 12.5.8.4. Australia
      • 12.5.8.5. Rest of Asia-Pacific
  • 12.6. Middle East and Africa
    • 12.6.1. Introduction
    • 12.6.2. Key Region-Specific Dynamics
    • 12.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
    • 12.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Class
    • 12.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Route of Administration
    • 12.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 12.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

13. Competitive Landscape

  • 13.1. Competitive Scenario
  • 13.2. Market Positioning/Share Analysis
  • 13.3. Mergers and Acquisitions Analysis

14. Company Profiles

  • 14.1. F. Hoffmann-La Roche Ltd.
    • 14.1.1. Company Overview
    • 14.1.2. Product Portfolio and Description
    • 14.1.3. Financial Overview
    • 14.1.4. Key Developments
  • 14.2. Teva Pharmaceutical Industries Ltd.
  • 14.3. Sanofi S.A
  • 14.4. Pfizer Inc.
  • 14.5. GSK plc
  • 14.6. Novartis AG
  • 14.7. AstraZeneca
  • 14.8. Johnson & Johnson Private Limited
  • 14.9. Sun Pharmaceutical Industries Ltd.
  • 14.10. Merck & Co., Inc

LIST NOT EXHAUSTIVE

15. Appendix

  • 15.1. About Us and Services
  • 15.2. Contact Us